CLOs on the Move

Lundbeck

www.lundbeck.com

 
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company`s products are targeted at disease areas such as depression, schizophrenia, Parkinson`s disease and Alzheimer`s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.lundbeck.com
  • Six Parkway North Suite 400
    Deerfield, IL USA 60015
  • Phone: 847.282.1000

Executives

Name Title Contact Details
Puja Leekha
Vice President, Chief Compliance Officer and Corporate Counsel Profile

Similar Companies

Advanced Accelerator Applications

Advanced Accelerator Applications is a pharmaceutical group specialized in the field of nuclear medicine.

Banziger Systems

Banziger Systems is a Emeryville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TRx Pharma

TRx Pharma is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pulmocide

Pulmocide is a biotechnology company focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.

Edgewise Therapeutics

Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it`s Series B financing round which will support the advancement of Edgewise Therapeutic`s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company`s pipeline. The company`s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.